In a clinical trial conducted by Ji Xu et al. in 2019, targeting CAR against BCMA antigen in 17 patients with multiple myeloma (RRMM) after lymphatic chemotherapy has shown promising results and the overall response rate was 88.2% [182]. Here, TNFRSF17 is linked to plasma cell myeloma.